On 21 January 2021, at the "Shenzhen Famous Brand" review meeting hosted by the Shenzhen General Industry Federation, Shenzhen Beike Biotechnology Co., Ltd. stood out from many brands with its high market share, high integrity and high brand awareness, winning the "Shenzhen Famous Brand" honor; the public announcement was successfully completed on 28 January!
The "Shenzhen Famous Brand" cultivation and evaluation activity was launched in April 2003 with the issuance of municipal government document Shen Fu [2003] No. 64, which explicitly entrusted the Shenzhen General Industry Federation with organizing this activity to drive enterprises to build brands and create reputable brands. To date the activity has been carried out for 18 sessions, producing more than 800 "Shenzhen Famous Brands". According to statistics, although these enterprises represent only 0.4‰ of the city's total enterprises, their combined sales account for 48.6% of the city's total enterprise sales. Many of these famous brands rank first in domestic market share in their segment, making outstanding contributions to Shenzhen's high-quality and brand development.
The "Shenzhen Famous Brand" cultivation and evaluation activity entails preliminary review by the Secretariat of the Shenzhen Famous Brand Evaluation Committee, on-site review of internal management systems, public voting, industry-position evaluation, brand-value assessment, plenary review by the evaluation committee and other procedures, with on-site notarization by the Shenzhen Notary Office. A total of 59 enterprises with high market share, high integrity and high brand awareness made this round's "Shenzhen Famous Brand" list. With its outstanding overall strength, Beike Biotech successfully made the list, joining Shenzhen leading enterprises such as Huawei and Mindray as a "Shenzhen Famous Brand".
Founded in 2005, Beike Biotech has worked deeply for many years in stem cell basic research and clinical translation. Upholding the core philosophy that "quality is the lifeblood of the enterprise", the company has insisted on R&D and technological innovation, rigorously controlled product quality, and earned visibility and reputation through its rigorous and meticulous approach. It has become a backbone force in China's stem cell clinical research field that cannot be ignored.
Strength forges glory; quality builds brilliance! Beike Biotech has consistently let professionalism and quality speak for it, putting innovation at the top of its priorities. As of November 2020, the company has filed 108 patents in the cell technology field, of which 56 have been granted. The innovative "Comprehensive Cell Bank + Regional Cell Preparation Center + Cell Quality Inspection Platform" industrial development model provides an innovative public technology platform and infrastructure for the clinical translation of cell therapy technology, while also laying a data foundation for the future development of AI + biomedicine. In January 2020, Beike Biotech's research outcome "Key Technical Innovation and Clinical Application of Allogeneic Mesenchymal Stem Cells in Treating Refractory Lupus Erythematosus" received the 2019 National Technological Invention Award.
While building its own strength and brand, Beike Biotech has also actively fulfilled its social responsibility. In 2020, in the face of the sudden COVID-19 outbreak, Beike Biotech rapidly responded to the country's call and actively participated in tackling technical challenges. In partnership with the Third People's Hospital of Shenzhen, the company applied for and was granted approval for the project "Clinical Research on Treating Severe Pneumonia Caused by Coronavirus with Human Umbilical Cord Mesenchymal Stem Cells" under the Guangdong Department of Science and Technology's "Guangdong Emergency Special Project on Scientific and Technological Tackling for the Prevention and Control of Novel Coronavirus Infection". Beike Biotech's project "Drug Development for Mesenchymal Stem Cell Therapy of COVID-19" was also approved as a key special project under the Ministry of Science and Technology's "Science and Technology Helping the Economy 2020" initiative.
To wear the crown is to bear its weight! This honor is both an affirmation of Beike Biotech's long-standing efforts and a spur and source of encouragement for the company's future development. 2021 is a new starting point following the 40th anniversary of the establishment of the Shenzhen Special Economic Zone. As a "Shenzhen Famous Brand", Beike Biotech will continue to drive development through innovation, leverage the policy advantages of the Greater Bay Area to accelerate the upgrade of products and services, continuously deepen its product technology R&D capability, further expand its brand influence, and use its own development to drive the stem cell industry toward higher-quality development, contributing more to Shenzhen's growth.
